Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Obio Technology (Shanghai) Corp. Ltd. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to MCCORMICK, CATHERINE LYNN, who is the busiest examiner for the portfolio with 1 pending office action. The portfolio's current activity is limited to 1 distinct examiner and 1 distinct art unit. With 1 pending office action total, the company's current prosecution workload is highly centralized.
The involvement of only 1 distinct examiner, MCCORMICK, CATHERINE LYNN, means that the immediate patenting goals for this portfolio are tied to the outcome of a single case. This focus within 1 distinct art unit suggests that the company is pursuing a specific technical path within the biotechnology sector, requiring a targeted response to the examiner's findings. This streamlined environment can lead to more predictable prosecution timelines and a more cohesive patent strategy. Practitioners should note that this centralized approach allows for a more efficient use of resources when responding to USPTO communications. The successful resolution of this single pending matter will be a vital step in securing the company's intellectual property in the Biotechnology & Pharmaceuticals area. By focusing on the feedback from a single examiner, the company can ensure its patenting goals are met with precision, clarity, and technical accuracy.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCCORMICK, CATHERINE LYNN | 1 | 50.0% | +42.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18265857 | EXOGENOUS GENE CONTROLLABLE EXPRESSION VIRUS PACKAGING VECTOR AND PACKAGING METHOD | MCCORMICK, CATHERINE LYNN | — |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18265857 | EXOGENOUS GENE CONTROLLABLE EXPRESSION VIRUS PACKAGING VECTOR AND PACKAGING METHOD | MCCORMICK, CATHERINE LYNN | 1638 | §103 | Final Rejection | — | Pending | Jun 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial